Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen (Nasdaq: ISPC) has launched a new Open Feasibilities Dashboard on its iSpecimen Marketplace®, enhancing transparency for supplier partners in the biospecimen procurement process. This feature allows suppliers to easily review potential research projects and flag high-priority specimens for quicker assessments. The dashboard aims to address existing limitations in the biospecimen sourcing process, ultimately facilitating more efficient collaboration between researchers and healthcare providers. This update supports the company's mission to advance medical research.
iSpecimen (Nasdaq: ISPC), an online marketplace connecting scientists with healthcare specimen providers, will announce its third quarter financial results for the period ending September 30, 2022, before market open on November 8, 2022. An audio webcast and conference call will be held on the same day at 8:30 a.m. Eastern Time, featuring remarks from Tracy Curley, Interim CEO and CFO. A replay will be available until November 22, 2022.
For more information, visit www.ispecimen.com.
iSpecimen (Nasdaq: ISPC) has launched its Marketplace Onsite program to enhance support for biospecimen provider partners. By embedding coordinators at select partner sites, the program streamlines the fulfillment of sample and data requests, thereby reducing strain on staff. The initiative aims to expand the provider network, increase access to high-demand biospecimens, and improve revenue growth. Interim CEO Tracy Curley emphasized the program's potential to address supplier constraints and facilitate vital medical research.
iSpecimen Inc. (Nasdaq: ISPC) announced a leadership change on September 22, 2022, with Tracy Curley appointed as interim CEO, replacing Christopher Ianelli. Ianelli's departure was effective September 21, 2022, due to the non-renewal of his employment agreement. Alongside Ianelli, Jill Mullan, COO, is also leaving on October 24, 2022. The Board aims to reassure stakeholders about the company’s stability, citing a strong business position. Curley maintains confidence in the leadership team to continue operational effectiveness.
iSpecimen (Nasdaq: ISPC) announced that CEO Christopher Ianelli will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City.
The corporate presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET. Interested attendees can register here. iSpecimen offers a marketplace connecting scientists with healthcare specimen providers.
iSpecimen Inc. (Nasdaq: ISPC) reported Q2 2022 results, with revenue of approximately $2.3 million, down from $2.9 million in Q2 2021, primarily due to decreased COVID-19 specimen sales. General specimen revenue increased by 8% year-over-year, totaling approximately $2.2 million. The company added new suppliers focused on oncology and cardiovascular research, growing its unique supplier organizations to 214. Despite external challenges, the company aims to improve its market position through technological advancements and strategic investments.
iSpecimen Inc. (Nasdaq: ISPC) will announce its financial results for Q2 2022 on August 4, 2022, before market opening. The announcement will be followed by a conference call at 8:30 a.m. ET, featuring executive remarks from CEO Christopher Ianelli and other key leaders. Investors can access the call via phone or webcast, with a replay available until August 18, 2022. iSpecimen operates an online marketplace linking researchers with healthcare specimen providers, facilitating essential medical research.
iSpecimen (Nasdaq: ISPC) announced the addition of new global biospecimen suppliers to its Marketplace, enhancing research capabilities for oncology and cardiovascular disease. The new suppliers include a U.S.-based cancer-focused biobank and a European biobank with extensive health data from participants aged 45 to 75. These biospecimens, including pre- and post-treatment samples, are expected to aid in clinical research for treatments, addressing critical health issues as cancer and cardiovascular diseases remain leading causes of death in the U.S.
iSpecimen (Nasdaq: ISPC) has appointed Evan Cox as Vice President of Product Management, effective immediately. With nearly two decades of experience in healthcare product management, Cox will oversee the growth of the iSpecimen Marketplace™. The company's CEO, Christopher Ianelli, stated that Cox's expertise in technology solutions will be crucial for enhancing the marketplace. Previously, Cox led product management at Definitive Healthcare and has worked with Change Healthcare and WebMD. His focus will be on meeting the evolving needs of researchers and healthcare organizations.
iSpecimen (NASDAQ: ISPC) presented three key discussions at the ISBER Annual Meeting in Atlanta, focusing on the evolution of biobanking through advanced technology.
Chief Operating Officer Jill Mullan outlined how precision medicine drives the need for 'just-in-time' biospecimen collections, leveraging five years of data from the iSpecimen Marketplace. Key insights highlighted the transition from traditional inventory methods to a dynamic, online inventory system.
Additional talks included the journey of iSpecimen from ideation to IPO and an interactive demo of the enhanced Marketplace platform.
FAQ
What is the current stock price of iSpecimen (ISPC)?
What is the market cap of iSpecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
